LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Seegene Unveils Innovative Laboratory-on-Wheels Facility Designed for Mass On-Site COVID-19 PCR Testing

By LabMedica International staff writers
Posted on 30 Jun 2021
Print article
Image: The Mobile Station (Photo courtesy of Seegene, Inc.)
Image: The Mobile Station (Photo courtesy of Seegene, Inc.)
Seegene, Inc. (Seoul, Korea) has introduced MOBILE STATION, an innovative laboratory-on-wheels facility that is designed to deploy the gold standard PCR testing solution to anywhere community-based testing is needed.

While many countries around the world are planning to re-open their borders, schools, and public-use facilities, Seegene’s new deployable container laboratory is considered an ideal option for conducting mass PCR testing in such locations. Also, the MOBILE STATION can be mobilized anytime, allowing more people to utilize molecular diagnostics when needed. MOBILE STATION sets the new bar of PCR lab setting with its ability to deliver effective testing solutions to anywhere testing is needed. PCR testing has been normally conducted only at fixed space due to concerns of cross-contamination. However, the MOBILE STATION, with Seegene's technology and know-how gained through operation of South Korea's largest reference laboratory, has already minimized the overall risks of aerosol contamination posed in PCR process by installing Class 2 (A2) Bio-Safety Cabinet and negative pressure room.

From sample collection to automated interpretation of results, it offers streamlined and automated workflow backed by the company's All-in-One platform thereby allowing equitable access to health care for the public. Seegene's All-in-One platform, when fully utilized, can conduct up to 7500 tests per day with a turnaround time of 3.5 hours. Seegene's pioneering concept of the mobile laboratory is expected to play a significant role in stopping the current pandemic since the company offers unparalleled PCR testing solution with its exclusive multiplex assays. The MOBILE STATION is also fully compatible with Seegene's more than 150 multiplex assay menus including tests for respiratory infectious pathogens, HPV, STI, and GI.

Seegene has also introduced Combo Swab, a self-administrable sample collection device. In comparison to nasopharyngeal swab, typically used in sampling for COVID-19 PCR testing, in which health care providers collect samples by inserting a swab deep inside nostrils, Combo Swab allows individuals to simply collect samples with two individual swabs through swirling around their nasal and oral cavity by two individual swabs without any discomfort. In addition, Combo Swab with dual sample collection showed the same accuracy compared to nasopharyngeal swab. Self-sample collection availability of Combo Swab along with provisional space scalability of MOBILE STATION enables mass testing to be processed in a quicker time and more efficient manner than the conventional process.

"As COVID-19 is likely to become endemic, the MOBILE STATION will play a key role in not only detecting COVID-19, but also closely monitoring other new viruses that can threaten our daily lives in the future," said Min-cheol Lee, Seegene's Chief Technology Officer. "Seegene's multiple virus variant detection kits can detect the new strains of virus and prevent them from turning into an additional outbreak of subsequent pandemic waves."




Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.